Novartis’ Kisqali reduces cancer recurrence risk in late-stage NATALEE trial
The late-stage trial evaluated patients with Stage II and III hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-)…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
05 Jun 23
The late-stage trial evaluated patients with Stage II and III hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-)…
05 Jun 23
Vorasidenib met its primary endpoint of progression free survival per the blinded independent review committee and achieved its…
05 Jun 23
Starpharma is progressing discussions with potential commercial partners in Malaysia, with the view of distributing VIRALEZE through local…
02 Jun 23
Lynparza is a PARP inhibitor and the first targeted treatment to block DNA damage response (DDR) in cells/tumours…
02 Jun 23
The European approval is based on Phase 3 data from the SUNSHINE and SUNRISE trials which enrolled more…
02 Jun 23
SYMPLIFY Results Demonstrate Strong Performance of GRAIL’s Multi-Cancer Early Detection Methylation-Based Platform in Individuals Presenting With Non-Specific Signs…
02 Jun 23
Data support that antibiotic aztreonam-avibactam (ATM-AVI) is effective and well-tolerated in treating infections caused by Gram-negative bacteria, with…
01 Jun 23
In the trial, the number of new gadolinium-enhancing (GdE) T1-lesions was lowered by 89% and 79% in the…
01 Jun 23
The phase 2 study was evaluating upadacitinib 30mg alone and in combination (ABBV-599 high dose) in systemic lupus…
01 Jun 23
The scientists found that the disorder has an overactive version of the STAT4 protein, which controls inflammation and…